18th Feb 2016 08:08
LONDON (Alliance News) - Allergy Therapeutics PLC on Thursday said it has completed patient enrolment for its phase 2b dose-finding study in the US.
The GrassMATAMPL product is an ultra-short course subcutaneous allergen specific immunotherapy administered to patients prior to the grass pollen season.
The total patient enrolment for the study was 250 patients and headline data from the study is expected by the end of the first half of 2016, which Allergy expects to pave the way to start phase 3 studies in the US.
Allergy shares were untraded early Thursday, having last traded at 26.00 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Allergy Thera.